Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Accounts Payables (2016 - 2025)

United Therapeutics' Accounts Payables history spans 17 years, with the latest figure at $488.0 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 41.65% year-over-year to $488.0 million; the TTM value through Dec 2025 reached $488.0 million, up 41.65%, while the annual FY2025 figure was $488.0 million, 41.65% up from the prior year.
  • Accounts Payables for Q4 2025 was $488.0 million at United Therapeutics, up from $468.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $488.0 million in Q4 2025 and bottomed at $165.0 million in Q1 2021.
  • The 5-year median for Accounts Payables is $295.0 million (2023), against an average of $290.5 million.
  • The largest annual shift saw Accounts Payables dropped 6.63% in 2021 before it skyrocketed 51.48% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $174.6 million in 2021, then surged by 31.67% to $229.9 million in 2022, then rose by 29.62% to $298.0 million in 2023, then grew by 15.6% to $344.5 million in 2024, then surged by 41.65% to $488.0 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Accounts Payables are $488.0 million (Q4 2025), $468.0 million (Q3 2025), and $432.0 million (Q2 2025).